GlaxoSmithKline(GSK.US) acquires 35 Pharma for $950 million, focusing on cardiovascular drug development

2026-03-10 10:53:27

Abstract generation in progress

GSK has agreed to acquire 35Pharma Inc., a biotech company with early-stage hypertension drug assets. This move marks the British pharmaceutical giant’s expansion into the cardiovascular drug sector.

In a statement on Wednesday, GSK said it will acquire the privately held Canadian company for $950 million in cash.

This deal signifies a strategic shift for the UK pharmaceutical company, which previously had a smaller pipeline focused on affecting heart and metabolic system diseases. New CEO Luke Miels faces pressure to increase the company’s drug pipeline as he seeks to offset the impact of patent expirations for a major HIV drug.

GSK’s biggest current financial challenge is the upcoming patent expiration around 2028 for its flagship HIV drugs, such as Dovato.

On January 20, GSK also announced the acquisition of U.S.-listed pharmaceutical company RAPT Therapeutics. Its core asset is a long-acting anti-IgE monoclonal antibody, JYB1904, introduced from Jiyu Medicine in December 2024, mainly used to treat food allergies, chronic spontaneous urticaria, asthma, and other conditions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.